The FDA has granted Imfinzi priority review status. The US FDA sBLA submission acceptance is an important milestone for IMFINZI in a disease state where patients need better treatment
Further, side effects were generally manageable and primarily mild to moderate in severity. The results [Abstract #OA 05.06] were presented by Professor Benjamin Solomon, lead investigator and medical
The FDA also previously granted Breakthrough Therapy Designation for this application, which is the seventh indication for which Opdivo has received this designation. “Priority review of our sBLA
The data is being presented at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Meeting in London, United Kingdom, by Christiane Querfeld,
Nivolumab works by binding to certain proteins in cells. This then stimulates the body’s immune system to attack cancerous cells and destroy them. When NICE first reviewed nivolumab,
"We've seen promising evidence that WP1066 has potent anticancer effects in animal tumor models due to its unique mode of action," commented Walter Klemp, Chairman and CEO of
Characterized by the World Health Organization as a "neglected tropical disease," leprosy (also known as Hansen's disease) is one of the most ancient diseases known to humankind and
The study hit statistical significance for the primary endpoint and all secondary endpoints evaluated for the topline results and demonstrated the ability to normalize bowel movements. The primary
Currently, there are no FDA approved treatments for patients with non-metastatic CRPC. This submission is based on Phase 3 data from the pivotal ARN-509-003 (SPARTAN) clinical trial, which
The application for Gilotrif is currently under review for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.